Menu
← Oncology Approval Tracker
FDA DECISION ·
Imbruvica
ibrutinib · Pharmacyclics / AbbVie
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Treatment of chronic graft-versus-host disease after failure of at least one line of systemic therapy in patients age one or older, expanding the prior adult use.
LAMPGEN ANALYSIS
Why it matters
The expansion provides a pediatric systemic option after prior treatment failure.
What research teams should watch
Document transplant and prior systemic therapy, then verify pediatric dose and formulation with the transplant team.
PRIMARY RECORDS